Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Group 2.5 Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 15, 2026, 7:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

NCT05806138
View directory record Official record
Conditions
Breast Cancer, Cardiac Dysfunction
Interventions
Vericiguat, Optimal medical therapy
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 15, 2026, 7:54 AM EDT
Not listed Phase 1Phase 2 Interventional

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

NCT03525418
View directory record Official record
Conditions
HLHS
Interventions
Longeveron Mesenchymal Stem Cells
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
1 Day to 1 Year
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00731120
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 15, 2026, 7:54 AM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 15, 2026, 7:54 AM EDT
Recruiting Not applicable Interventional

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

NCT07078682
View directory record Official record
Conditions
Uterine Fibroids, Leiomyoma, Menstrual Pain
Interventions
Elix Daily Harmony
Dietary Supplement
Lead sponsor
Zenchi, Inc.
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Not applicable Interventional Results available

Self-Defense Training in Women With Trauma

NCT01380379
View directory record Official record
Conditions
Depression, Anxiety, Stress Disorders, Post-Traumatic
Interventions
Life skills and self-defense training
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Meditation and Exercise for Prevention of Acute Respiratory Infection

NCT01057771
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Meditation, Exercise
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Not applicable Interventional Results available

Brain Health Together: A Live-Streaming Group-Based Digital Program

NCT05818423
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Decline, Cognitive Deterioration, Cognitive Deficits, Mild, Cognitive Impairment, Mild
Interventions
Brain Health Academy, Brain Health Together, Maintain Brain Health Together
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00448201
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
10 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 15, 2026, 7:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness-Based Stress Reduction, Health Education and Exercise

NCT02665481
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
MBSR, Exercise, Health Education
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 84 Years
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
San Diego, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 15, 2026, 7:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Online Mindfulness-Based College for Young Adults

NCT04733300
View directory record Official record
Conditions
Depressive Symptoms, Loneliness, Sedentary Behavior, Mindfulness, Physical Activity, Diet, Sleep, Emotional Regulation, Alcohol Consumption, Youth, Stress, Psychological
Interventions
Mindfulness-Based College for Young Adults, Health Education for Young Adults
Behavioral · Other
Lead sponsor
Eric Loucks
Other
Eligibility
18 Years to 29 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Not applicable Interventional Results available

Assessment of Acute Disease to Reduce Imaging Costs

NCT01059500
View directory record Official record
Conditions
Acute Coronary Syndrome, Pulmonary Embolism
Interventions
Webtool
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Jackson, Mississippi • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00730691
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 1 Interventional

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

NCT06118515
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection
Interventions
Letermovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 90 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 15, 2026, 7:54 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 1 Interventional Results available

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

NCT01525238
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 15, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Sep 15, 2026, 7:54 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 15, 2026, 7:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking

NCT07055217
View directory record Official record
Conditions
Repetitive Negative Thinking, Neurofeedback
Interventions
Mindfulness Training, Mindfulness-based Neurofeedback (Real mbNF), Sham mindfulness-based neurofeedback (Sham mbNF)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 15, 2026, 7:54 AM EDT